ReviewJournal of medicinal chemistry2026
Beyond α-GalCer: Medicinal Chemistry Insights Driving Structural Evolution of CD1d Ligands.
Review in Journal of medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
CD1d-restricted glycolipids have emerged as a cornerstone in the development of next-generation immunotherapies. This perspective provides a comprehensive update on structure-activity relationships, specifically examining how modifications of the prototypical CD1d ligand α-galactosylceramide (α-GalCer) to the galactosyl headgroup, phytosphingosine base, and fatty acyl chain dictate the modulation of invariant natural killer T (iNKT) cell responses. We explore the key pharmacophores and receptor interactions that polarize subsequent immune response toward either a pro-inflammatory Th1 or an anti-inflammatory Th2 phenotype. Building upon the structural evolution of sophisticated chemotypes, we evaluate the potential of these agonists in synergistic combinations with other adjuvants. Furthermore, we highlight the emerging transition toward fully synthetic self-adjuvanting vaccines, which ensure cellular colocalization and coordinated activation by covalently integrating antigens with glycolipid agonists. Collectively, these advancements underscore the transformative potential of tailored glycolipid design in engineering specific and durable immunity against cancer and infectious diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.